메뉴 건너뛰기




Volumn 65, Issue 5, 2011, Pages 559-566

Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer

Author keywords

[No Author keywords available]

Indexed keywords

DEGARELIX; FOLLITROPIN; LEUPRORELIN; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

EID: 79955012057     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02637.x     Document Type: Article
Times cited : (23)

References (24)
  • 1
    • 0026098581 scopus 로고
    • Gonadotrophin-releasing hormone and its analogues
    • Conn PM, Crowley WF Jr,. Gonadotrophin-releasing hormone and its analogues. N Engl J Med 1991; 324: 93-103.
    • (1991) N Engl J Med , vol.324 , pp. 93-103
    • Conn, P.M.1    Crowley, Jr.W.F.2
  • 2
    • 33645915874 scopus 로고    scopus 로고
    • Comparison of single-agent androgen suppression for advanced prostate cancer
    • Lepor H,. Comparison of single-agent androgen suppression for advanced prostate cancer. Rev Urol 2005; 7 (Suppl. 5): S3-12.
    • (2005) Rev Urol , vol.7 , Issue.SUPPL. 5
    • Lepor, H.1
  • 3
    • 0022367715 scopus 로고
    • Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer
    • Waxman J, Man A, Hendry WF, et al., Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. Br Med J 1985; 291: 1387-8. (Pubitemid 16212355)
    • (1985) British Medical Journal , vol.291 , Issue.6506 , pp. 1387-1388
    • Waxman, J.1    Man, A.2    Hendry, W.F.3
  • 4
    • 0025688334 scopus 로고
    • Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate
    • Thompson IM, Zeidman EJ, Rodriguez FR,. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol 1990; 144: 1479-80.
    • (1990) J Urol , vol.144 , pp. 1479-1480
    • Thompson, I.M.1    Zeidman, E.J.2    Rodriguez, F.R.3
  • 5
    • 0022973082 scopus 로고
    • Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate
    • Boccon-Gibod L, Laudat MH, Dugue MA, et al., Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by LHRH analogs in the treatment of metastatic carcinoma of the prostate. Eur Urol 1986; 12: 400-2. (Pubitemid 17212964)
    • (1986) European Urology , vol.12 , Issue.6 , pp. 400-402
    • Boccon-Gibod, L.1    Laudat, M.H.2    Dugue, M.A.3    Steg, A.4
  • 6
    • 50849110501 scopus 로고    scopus 로고
    • Degarelix: A novel gonadotrophin-releasing hormone (GnRH) blocker - Results from a one-year, multicentre, randomised, phase 2 dose-finding study in the treatment of prostate cancer
    • Van Poppel H, Tombal B, de la Rosette JM, et al., Degarelix: a novel gonadotrophin-releasing hormone (GnRH) blocker-results from a one-year, multicentre, randomised, phase 2 dose-finding study in the treatment of prostate cancer. Eur Urol 2008; 54: 805-13.
    • (2008) Eur Urol , vol.54 , pp. 805-813
    • Van Poppel, H.1    Tombal, B.2    De La Rosette, J.M.3
  • 7
    • 56649116179 scopus 로고    scopus 로고
    • The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
    • Klotz L, Boccon-Gibod L, Shore ND, et al., The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008; 102: 1531-8.
    • (2008) BJU Int , vol.102 , pp. 1531-1538
    • Klotz, L.1    Boccon-Gibod, L.2    Shore, N.D.3
  • 8
    • 53249121469 scopus 로고    scopus 로고
    • A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America
    • Gittelman M, Pommerville PJ, Persson B-E, et al., A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 2008; 180: 1986-92.
    • (2008) J Urol , vol.180 , pp. 1986-1992
    • Gittelman, M.1    Pommerville, P.J.2    Persson, B.-E.3
  • 9
    • 79955044776 scopus 로고    scopus 로고
    • LUPRON DEPOT 7.5 mg Package Insert, 03-A067-R19; Revised: December, 2007
    • LUPRON DEPOT 7.5 mg Package Insert, 03-A067-R19; Revised: December, 2007.
  • 11
    • 0033900377 scopus 로고    scopus 로고
    • Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: The case for monitoring serum testosterone and a treatment decision algorithm
    • Oefelein MG, Cornum R,. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000; 164: 726-9. (Pubitemid 30637611)
    • (2000) Journal of Urology , vol.164 , Issue.3 , pp. 726-729
    • Oefelein, M.G.1    Cornum, R.2
  • 12
    • 33746901635 scopus 로고    scopus 로고
    • Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer
    • DOI 10.1159/000093907
    • Morote J, Esquena S, Abascal JM, et al., Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urol Int 2006; 77: 135-8. (Pubitemid 44195773)
    • (2006) Urologia Internationalis , vol.77 , Issue.2 , pp. 135-138
    • Morote, J.1    Esquena, S.2    Abascal, J.M.3    Trilla, E.4    Cecchini, L.5    Raventos, C.X.6    Catalan, R.7    Reventos, J.8
  • 13
    • 29044442028 scopus 로고    scopus 로고
    • Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer
    • DOI 10.1016/j.eururo.2005.09.009, PII S0302283805005816
    • Yri OE, Bjoro T, Fossa SD,. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol 2006; 49: 54-8. (Pubitemid 41789955)
    • (2006) European Urology , vol.49 , Issue.1 , pp. 54-58
    • Yri, O.E.1    Bjoro, T.2    Fossa, S.D.3
  • 14
    • 77149159440 scopus 로고    scopus 로고
    • Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: Prognostic significance?
    • Perachino M, Cavalli V, Bravi F,. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 2010; 105: 648-51.
    • (2010) BJU Int , vol.105 , pp. 648-651
    • Perachino, M.1    Cavalli, V.2    Bravi, F.3
  • 16
    • 77956640362 scopus 로고    scopus 로고
    • Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke
    • Hayes JH, Chen M-H, Moran BJ,. Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke. BJU Int 2010; 106: 979-85.
    • (2010) BJU Int , vol.106 , pp. 979-985
    • Hayes, J.H.1    Chen, M.-H.2    Moran, B.J.3
  • 17
    • 34250345421 scopus 로고    scopus 로고
    • Determining the optimal initiation and maintenance doses of degarelix for hormone therapy of prostate cancer patients
    • Iversen P, Van Poppel H, Tammela T, et al., Determining the optimal initiation and maintenance doses of degarelix for hormone therapy of prostate cancer patients. Urology 2006; 68 (Suppl. 5A): 102.
    • (2006) Urology , vol.68 , Issue.SUPPL. 5A , pp. 102
    • Iversen, P.1    Van Poppel, H.2    Tammela, T.3
  • 18
    • 0030906899 scopus 로고    scopus 로고
    • High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteinizing hormone, follicle- stimulating hormone, and testosterone in normal men
    • Behre HM, Kleisch S, Pühse G, et al., High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress luteinizing hormone, follicle-stimulating hormone and testosterone in normal men. J Clin Endocrinol Metab 1997; 82: 1403-8. (Pubitemid 27200409)
    • (1997) Journal of Clinical Endocrinology and Metabolism , vol.82 , Issue.5 , pp. 1403-1408
    • Behre, H.M.1    Kliesch, S.2    Puhse, G.3    Reissmann, T.4    Nieschlag, E.5
  • 19
    • 0035516095 scopus 로고    scopus 로고
    • A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer
    • McLeod D, Zinner N, Tomera K, et al., A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001; 58: 756-61.
    • (2001) Urology , vol.58 , pp. 756-761
    • McLeod, D.1    Zinner, N.2    Tomera, K.3
  • 22
    • 33646036678 scopus 로고    scopus 로고
    • FSH directly regulates bone mass
    • Sun L, Peng Y, Sharrow AC, et al., FSH directly regulates bone mass. Cell 2006; 125: 247-60.
    • (2006) Cell , vol.125 , pp. 247-260
    • Sun, L.1    Peng, Y.2    Sharrow, A.C.3
  • 23
    • 77954125660 scopus 로고    scopus 로고
    • FSHR gene polymorphisms influence bone mineral density and bone turnover in postmenopausal women
    • Rendina D, Gianfrancesco F, De Filipo G, et al., FSHR gene polymorphisms influence bone mineral density and bone turnover in postmenopausal women. Eur J Endocrinol 2010; 163: 165-72.
    • (2010) Eur J Endocrinol , vol.163 , pp. 165-172
    • Rendina, D.1    Gianfrancesco, F.2    De Filipo, G.3
  • 24
    • 84855309320 scopus 로고    scopus 로고
    • Open label, exploratory study of degarelix as second-line hormonal therapy in patients with prostate cancer (CS27)
    • Miller K, Rüssel C, Goble S, et al., Open label, exploratory study of degarelix as second-line hormonal therapy in patients with prostate cancer (CS27). Eur Urol Suppl 2010; 9: 76.
    • (2010) Eur Urol Suppl , vol.9 , pp. 76
    • Miller, K.1    Rüssel, C.2    Goble, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.